Sativex + Sativex + Sativex + Placebo + Marinol + Marinol
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Evaluation of Abuse Potential of Sativex
Conditions
Evaluation of Abuse Potential of Sativex
Trial Timeline
Feb 1, 2008 → Jun 1, 2008
NCT ID
NCT01323569About Sativex + Sativex + Sativex + Placebo + Marinol + Marinol
Sativex + Sativex + Sativex + Placebo + Marinol + Marinol is a phase 1 stage product being developed by Jazz Pharmaceuticals for Evaluation of Abuse Potential of Sativex. The current trial status is completed. This product is registered under clinical trial identifier NCT01323569. Target conditions include Evaluation of Abuse Potential of Sativex.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01323569 | Phase 1 | Completed |
Competing Products
5 competing products in Evaluation of Abuse Potential of Sativex
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol Turbuhaler | AstraZeneca | Phase 1 | 33 |
| Avelox (Moxifloxacin, BAY12-8039) + Placebo | Bayer | Phase 1 | 30 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 30 |
| ETC-1002 | Esperion Therapeutics | Phase 1 | 28 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |